Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

LATE-BREAKING RESEARCH: PRACTICE MANAGEMENT
Abstract #PM07

Operation Angel on the Line: Oncology Pharmacist and Pharmacy Students Piloting a New Oral Chemotherapy Telehealth Clinic During the COVID-19 Pandemic

JHOP - March 2021 Vol 11 Special Feature - HOPA Abstracts, Chemotherapy, COVID-19

Presenter: Diana Tamer, PharmD, BCOP, Clinical Assistant Professor, University of Missouri-Kansas City

Co-Authors: Jake Wodtke, Pharmacy Student, PharmD Candidate, University of Missouri-Kansas City; Samira Zantout, Pharmacy Student, PharmD Candidate, University of Missouri-Kansas City; Timothy Schieber, Pharmacy Student, PharmD Candidate, University of Missouri-Kansas City

Background: Oral oncolytic agents continue to be on the forefront of cancer treatment advances. Although more convenient to patients, these treatments place significant responsibilities on patients and clinicians alike, to adhere to potentially complex regimens and schedules, and to monitor and manage serious side effects.1-3 Currently, no standardized guidelines exist for the outpatient management of patients receiving oral oncolytic agents. There is a significant need for patient and clinician education, standardized workflow, and further support for monitoring, to improve patients’ quality of life and treatment outcomes. For that reason, a telehealth clinic was launched by a clinical oncology pharmacy faculty and pharmacy student trainees at a community cancer center at the University of Missouri-Kansas City.

Objective: To describe the development of an oral chemotherapy telehealth clinic and its interventions at a community cancer center.

Methods: This study is a retrospective chart review of adult patients with cancer who were enrolled in the oral chemotherapy clinic at the University of Missouri-Kansas City cancer center between July 1, 2020, and October 30, 2020. Inclusion criteria included adult patients (age ≥18 years) with cancer who received treatment from an oncologist and had complete clinical notes from the provided telehealth service.

Results: During the study period, 59 (66% female) patients were included. The patients’ average age was 62.5 years. The race makeup consisted of white (N = 54; 91.5%), Asian (N = 3; 5.1%), and black or African American (N = 2; 3.4%). The average time since initiation of oral oncolytic therapy was 12.8 months. The average of number of comorbid conditions was 3.1. The average of number of interventions per visit was 2.9. The team made 174 interventions: 5% referrals to a primary care provider, 2% referrals to physical therapy, 1% referrals to a pain specialist, 4% referrals to a specialist, 2% referrals to social work or counseling services, 5% initiation of prescription medication, 16% initiating nonpharmacist recommendations, 1% discontinuing medications, 8% managing treatment-related adverse events, 6% adherence education, 9% symptom/disease management, 28% medication-reconciliation error, 5% drug interaction, 5% scheduling laboratory tests per visit, and 3% for scheduling follow-up visit with the provider (oncologist). The average patient-reported adherence was 99.1%. The average time spent to complete the visit was 25.3 minutes.

Conclusion: This study describes the establishment of a new standardized workflow for an oral chemotherapy telehealth clinic, including the clinic and student training, as well as clinic logistics and the type of interventions performed. This initiative to improve and standardize the oral chemotherapy workflow can lead to improved patient care and outcomes, while also providing a no-cost critical training opportunity for pharmacy students. This model can serve as a guidance to community cancer centers wishing to launch a similar initiative with limited resources.

  1. DeCardenas R, Helfrich JS. Oral therapies and safety issues for oncology practices: patient support is key to delivering safe oral chemotherapy. Oncol Issues. 2010;25:40-42.
  2. Weingart SN, Brown E, Bach PB, et al. NCCN task force report: oral chemotherapy. J Natl Compr Canc Netw. 2008;6(suppl 3):S1-S14.
  3. Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: a review from the patient’s perspective. Ther Clin Risk Manag. 2008;4:269-286.
Related Items
Safety and Antitumor Activity of Dostarlimab in Patients with Advanced or Recurrent DNA Mismatch Repair-Deficient or -Proficient Endometrial Cancer: Results from the GARNET Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Biomarkers, Clinical Trials, Gynecologic Cancers
Integration of a Clinical Pharmacist in a Phase 1 Clinical Trial Program
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials
Feasibility and Perceived Benefit of an Oral Chemotherapy Pharmacy Monitoring Program to Assess Symptom Burden and Medication Adherence in Patients with Cancer
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Chemotherapy, Oncology Pharmacy Protocols
The Incidence of Coring Between the Traditional Syringe and Needle Compounding Technique and Closed-System Transfer Devices
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Infusion Issues
Safety of Switching e-Prescribing Platform Body Surface Area Calculation from DuBois & DuBois to Mosteller on Active Chemotherapy Doses
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Chemotherapy
Impact of Drug Repository Program in a Rural Oncology Clinic
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Adverse Events, Oncology Pharmacy Programs
Evaluation of Treatment Abandonment and Delay with Anticancer Agents at an Outpatient Community Hospital Cancer Center Oral Chemotherapy Clinic: A Retrospective Cohort Analysis
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Adverse Events, Chemotherapy, Oncology Pharmacy Programs
Evaluation of the Relationship between Hypoalbuminemia and Oral Anticancer Drug-Related Adverse Events in Adults with Solid Tumor Malignancies
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Adverse Events
Worldwide Influenza and Pneumococcal Vaccination Rates in Patients with Multiple Myeloma, and the Impact of Vaccination on Infection, Hospitalization, and Death
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Multiple Myeloma, Vaccinations
The Incidence of Arterial and Venous Thromboembolism in Patients with Chronic Myeloid Leukemia or Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Who Are Treated with Ponatinib
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Leukemia, Thromboembolism
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.